$RPHM
Reneo Pharmaceuticals Inc

2024 Q3 Form 10-Q Financial Statement

#000095017024096411 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.774M
YoY Change -13.03%
% of Gross Profit
Research & Development $590.0K
YoY Change -95.9%
% of Gross Profit
Depreciation & Amortization $12.00K
YoY Change -71.43%
% of Gross Profit
Operating Expenses $6.364M
YoY Change -69.75%
Operating Profit -$6.364M
YoY Change -69.75%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.003M
YoY Change -33.49%
Pretax Income -$5.361M
YoY Change -72.55%
Income Tax
% Of Pretax Income
Net Earnings -$5.361M
YoY Change -72.51%
Net Earnings / Revenue
Basic Earnings Per Share -$0.16
Diluted Earnings Per Share -$0.16
COMMON SHARES
Basic Shares Outstanding 33.43M 33.42M
Diluted Shares Outstanding 33.42M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.67M
YoY Change -46.26%
Cash & Equivalents $35.97M
Short-Term Investments $40.70M
Other Short-Term Assets $1.316M
YoY Change -63.88%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $77.99M
YoY Change -46.7%
LONG-TERM ASSETS
Property, Plant & Equipment $81.00K
YoY Change -85.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $153.0K
YoY Change 93.67%
Total Long-Term Assets $727.0K
YoY Change -57.71%
TOTAL ASSETS
Total Short-Term Assets $77.99M
Total Long-Term Assets $727.0K
Total Assets $78.72M
YoY Change -46.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $64.00K
YoY Change -96.5%
Accrued Expenses $953.0K
YoY Change -91.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.348M
YoY Change -90.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $500.0K
YoY Change -71.8%
Total Long-Term Liabilities $500.0K
YoY Change -71.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.348M
Total Long-Term Liabilities $500.0K
Total Liabilities $1.848M
YoY Change -88.09%
SHAREHOLDERS EQUITY
Retained Earnings -$232.3M
YoY Change 35.59%
Common Stock $3.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $76.87M
YoY Change
Total Liabilities & Shareholders Equity $78.72M
YoY Change -46.83%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$5.361M
YoY Change -72.51%
Depreciation, Depletion And Amortization $12.00K
YoY Change -71.43%
Cash From Operating Activities -$6.807M
YoY Change -57.76%
INVESTING ACTIVITIES
Capital Expenditures $2.000K
YoY Change -60.0%
Acquisitions
YoY Change
Other Investing Activities $22.49M
YoY Change -132.6%
Cash From Investing Activities $22.49M
YoY Change -132.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -89.00K
YoY Change -100.14%
NET CHANGE
Cash From Operating Activities -6.807M
Cash From Investing Activities 22.49M
Cash From Financing Activities -89.00K
Net Change In Cash 15.59M
YoY Change -173.17%
FREE CASH FLOW
Cash From Operating Activities -$6.807M
Capital Expenditures $2.000K
Free Cash Flow -$6.809M
YoY Change -57.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001637715
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40315
dei Entity Registrant Name
EntityRegistrantName
Reneo Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2309515
dei Entity Address Address Line1
EntityAddressAddressLine1
18575 Jamboree Road, Suite 275-S
dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92612
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
283-0280
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
RPHM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33428808
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35970000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27632000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
40704000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
75331000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1316000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3659000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
77990000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
106622000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
81000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
134000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
493000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
599000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
153000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
81000
CY2024Q2 us-gaap Assets
Assets
78717000
CY2023Q4 us-gaap Assets
Assets
107436000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
64000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8717000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
953000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9129000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
331000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
331000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1348000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18177000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
492000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
642000
CY2024Q2 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
8000
CY2023Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
7000
CY2024Q2 us-gaap Liabilities
Liabilities
1848000
CY2023Q4 us-gaap Liabilities
Liabilities
18826000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33420808
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33420808
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33420808
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33420808
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
309140000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
307073000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-232261000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218474000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
76869000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
88610000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78717000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107436000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
590000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14400000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5533000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25389000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5774000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6639000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10396000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11771000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
6364000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
21039000
us-gaap Operating Expenses
OperatingExpenses
15929000
us-gaap Operating Expenses
OperatingExpenses
37160000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6364000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21039000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15929000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37160000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1003000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1508000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2142000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2522000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5361000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-19531000
us-gaap Net Income Loss
NetIncomeLoss
-13787000
us-gaap Net Income Loss
NetIncomeLoss
-34638000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-43000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-21000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
12000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5362000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19574000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13808000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34626000
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33420808
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33420808
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30215321
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30215321
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33420808
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33420808
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27640172
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27640172
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
88610000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1078000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-20000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8426000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
81242000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
989000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5361000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
76869000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
99970000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1157000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
55000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-15107000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
87084000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1207000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
282000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-43000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-19531000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
132528000
us-gaap Net Income Loss
NetIncomeLoss
-13787000
us-gaap Net Income Loss
NetIncomeLoss
-34638000
us-gaap Share Based Compensation
ShareBasedCompensation
2067000
us-gaap Share Based Compensation
ShareBasedCompensation
2364000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
83000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1644000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2011000
rphm Fair Value Changes Of Share Based Performance Award
FairValueChangesOfShareBasedPerformanceAward
1000
rphm Fair Value Changes Of Share Based Performance Award
FairValueChangesOfShareBasedPerformanceAward
847000
rphm Non Cash Lease Expense
NonCashLeaseExpense
129000
rphm Non Cash Lease Expense
NonCashLeaseExpense
241000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-27000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2360000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1542000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-16829000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6690000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-173000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-283000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27821000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25162000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
177000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
67750000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
132327000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
104000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
82000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
36248000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50504000
us-gaap Payments For Repurchase Of Private Placement
PaymentsForRepurchaseOfPrivatePlacement
89000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
4667000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
282000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-89000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64820000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8338000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10846000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27632000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19927000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35970000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9081000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10000
rphm Restructuring And Related Cost Remaining Number Of Full Time Employees
RestructuringAndRelatedCostRemainingNumberOfFullTimeEmployees
8
CY2024Q2 rphm Cash And Cash Equivalents At Carrying Value And Short Term Investments
CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments
76700000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4982790
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6365685
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
53558000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
53545000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
75324000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
75331000
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q4 rphm Accrued Clinical And Regulatory Expenses
AccruedClinicalAndRegulatoryExpenses
3661000
CY2023Q4 rphm Accrued Manufacturing Expense
AccruedManufacturingExpense
1100000
CY2024Q2 rphm Accrued Compensation Expense
AccruedCompensationExpense
386000
CY2023Q4 rphm Accrued Compensation Expense
AccruedCompensationExpense
3948000
CY2024Q2 rphm Accrued Other
AccruedOther
567000
CY2023Q4 rphm Accrued Other
AccruedOther
420000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
953000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9129000
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M12D
us-gaap Operating Lease Payments
OperatingLeasePayments
194000
us-gaap Operating Lease Payments
OperatingLeasePayments
142000
us-gaap Operating Lease Expense
OperatingLeaseExpense
148000
us-gaap Operating Lease Expense
OperatingLeaseExpense
241000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
195000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
371000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
285000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
851000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
28000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
823000
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10186555
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5301254
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.76
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
629964
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.9
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4671290
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.74
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
3348616
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
5.04
rphm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P6Y6M
rphm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue
0
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3516983
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.03
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
989000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1207000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2067000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2364000

Files In Submission

Name View Source Status
0000950170-24-096411-index-headers.html Edgar Link pending
0000950170-24-096411-index.html Edgar Link pending
0000950170-24-096411.txt Edgar Link pending
0000950170-24-096411-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img28451501_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rphm-20240630.htm Edgar Link pending
rphm-20240630.xsd Edgar Link pending
rphm-ex10_2.htm Edgar Link pending
rphm-ex10_3.htm Edgar Link pending
rphm-ex10_4.htm Edgar Link pending
rphm-ex10_5.htm Edgar Link pending
rphm-ex31_1.htm Edgar Link pending
rphm-ex31_2.htm Edgar Link pending
rphm-ex32_1.htm Edgar Link pending
Show.js Edgar Link pending
rphm-20240630_htm.xml Edgar Link completed